Physician profile

Matthew Brandes

Richmond, VA

NPI 1063904308

$1,067.80

in general payments reported to CMS, 2019-2025

4 companies · $461 in 2025

The $461 reported for 2025 was more than what 77% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$798.43
Travel and Lodging$155.68

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic, INC. $605.23 2023-2025 Abre, Concertotm
Inari Medical, INC. $340.18 2022-2023 Flowtriever Catheter, S, Ct Thrombectomy System Kit
Boston Scientific Corporation $102.60 2025 Accolade Sr
Angiodynamics, INC. $19.79 2023 Smart Port Ct

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Matthew Brandes

$1,067.80

in general payments reported 2019-2025

Years
2022-2025
Top company
Medtronic, INC.
Context
The $461 reported for 2025 was more than what 77% of providers received nationally.

https://glasscript.com/doctor/11435502/matthew-brandes

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.